Inozyme Pharma, Inc.
Inozyme Pharma, Inc. (INZY) Stock Overview
Explore Inozyme Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.
INZY Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Inozyme Pharma, Inc. (INZY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $3.28.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -2.41 and a market capitalization of 258.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Dr. Douglas A. Treco Ph.D.
67
321 Summer Street, Boston, MA
2020